Key statistics
On Tuesday, Zyversa Therapeutics Inc (ZVSA:NAQ) closed at 2.34, 12.50% above the 52 week low of 2.08 set on Sep 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.31 |
---|---|
High | 2.34 |
Low | 2.25 |
Bid | 1.33 |
Offer | 2.50 |
Previous close | 2.27 |
Average volume | 26.13k |
---|---|
Shares outstanding | 1.03m |
Free float | 1.02m |
P/E (TTM) | -- |
Market cap | 2.41m USD |
EPS (TTM) | -100.63 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:59 BST.
More ▼
Announcements
- ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
- ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
- ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
- ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
- ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
- ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
- ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
- ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
- ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
- ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
More ▼